08.02.2016, 09:13
Astellas Announces Personnel Changes and Organizational Changes
OREANDA-NEWS. Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.
1. Appointment of Senior Corporate Executive effective on April 1, 2016
2. Appointments of Corporate Executive effective on April 1, 2016
3. Resignation of Senior Corporate Executive effective on June 20, 2016
4. Resignations of Corporate Executive effective on June 20, 2016
5. New Corporate Executives effective on June 20, 2016
6. Personnel Changes effective on April 1, 2016
7. Personnel Changes of Affiliates effective on April 1, 2016
8. Appointment of Staff Executive Director effective on April 1, 2016
9. Organizational Changes effective on April 1, 2016
Healthcare Policy & CSR
A corporate division, Healthcare Policy & CSR, will be newly established by consolidating functions responsible for taking actions to improve patient access to health care. Vice President of Healthcare Policy & CSR will report to Chief Strategy Officer.
Medical Information Center
The name of Medical Information Center will be changed to Medical Communications, Japan.
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.
1. Appointment of Senior Corporate Executive effective on April 1, 2016
Name | New Title | Current Title |
Masao Yoshida | CEO's Office | President, Americas Operations |
2. Appointments of Corporate Executive effective on April 1, 2016
Name | New Title | Current Title |
Shouji Yokota | CEO's Office | Divisional Senior Vice President, Technology Product Management, Technology |
Takahisa Iizuka | CEO's Office | Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing |
Chihiro Yokota | Head of Japan/Asia Development, Development | Head of Japan/Asia Development, Development and Head of Medical Affairs, Japan |
Atsushi Kamide | Vice President, Healthcare Policy & CSR | Divisional Senior Vice President, Product Marketing, Japan Sales & Marketing |
Kiyotaka Hayashi | Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing | General Manager, Osaka Branch, Japan Sales & Marketing |
Chikashi Takeda | Corporate Vice President, Corporate Finance & Control | Corporate Vice President, Corporate Planning |
3. Resignation of Senior Corporate Executive effective on June 20, 2016
Name | Title (effective on April 1, 2016) |
Masao Yoshida | CEO's Office |
4. Resignations of Corporate Executive effective on June 20, 2016
Name | Title (effective on April 1, 2016) |
Shouji Yokota | CEO's Office |
Takahisa Iizuka | CEO's Office |
5. New Corporate Executives effective on June 20, 2016
Name | Title (effective on April 1, 2016) |
Naoki Okamura | Corporate Vice President, Corporate Planning |
Takuya Oshida | Senior Vice President, Head of Medical Affairs, Japan |
Yasuhiro Kanzaki | General Manager, Osaka Branch, Japan Sales & Marketing |
6. Personnel Changes effective on April 1, 2016
Name | New Title | Current Title |
James Robinson | President, Americas Operations | President, Astellas Pharma US, Inc. |
Kunihiko Kokubo | Head of Quality Assurance | Vice President, Quality Assurance, Japan, Asia & Oceania |
Takuya Oshida | Head of Medical Affairs, Japan | Vice President, Medical Science, Medical Affairs, Japan |
Naoki Okamura | Corporate Vice President, Corporate Planning | Corporate Vice President, Business Development |
Jun Kono | Corporate Vice President, Business Development | Vice President, Corporate Strategy & Communications, EMEA |
Koichiro Morihira | Vice President, Intellectual Property | Executive Director, Intellectual Property |
Motoi Aoki | Vice President, Quality Assurance, Japan, Asia & Oceania | Senior Director, Quality Assurance, EMEA |
Aiji Miyashita | Vice President, Clinical and Research Quality Assurance | Senior Director, Analysis & Pharmacokinetics Research Labs., Drug Discovery Research |
Akira Unami | Vice President, Drug Safety Research Labs., Drug Discovery Research | Senior Director, Drug Safety Research Labs., Drug Discovery Research |
Hideki Maeda | Vice President, Medical Science, Medical Affairs, Japan | Vice President, Medical Research, Medical Affairs, Japan |
Yasushi Ikeda | Vice President, Medical Research, Medical Affairs, Japan | Senior Director, Medical Science, Medical Affairs, Japan |
Naoko Sato | Vice President, Medical Communications, Japan, Medical Affairs, Japan | Vice President, Medical Information Center, Medical Affairs, Japan |
Katsutoshi Nakamura | Vice President, Technology Product Management, Technology | Executive Director, Technology Product Management, Technology |
Shigeru Ieda | Vice President, Process Chemistry Labs., Technology | General Manager, Astellas Pharma Tech Co., Ltd. |
Shiro Yamamoto | Divisional Senior Vice President, Product Marketing, Japan Sales & Marketing | Executive Director, Product Marketing, Japan Sales & Marketing |
Akihiro Takimoto | Vice President, Distribution Relations, Japan Sales & Marketing | Senior Director, Distribution Relations, Japan Sales & Marketing |
Norihito Matsunami | General Manager, Sapporo Branch, Japan Sales & Marketing | Senior Director, Nagoya Branch, Japan Sales & Marketing |
Masayuki Ohki | General Manager, Kanetsu Branch, Japan Sales & Marketing | General Manager, Yokohama Branch, Japan Sales & Marketing |
Sakakiya Hiroshi | General Manager, Yokohama Branch, Japan Sales & Marketing | Executive Director, Kobe Branch, Japan Sales & Marketing |
Yasuhiro Kanzaki | General Manager, Osaka Branch, Japan Sales & Marketing | General Manager, Sapporo Branch, Japan Sales & Marketing |
7. Personnel Changes of Affiliates effective on April 1, 2016
Name
|
New Title
|
Current Title
|
Akira Sekine
|
President, Astellas Learning Institute Co., Ltd.
|
Executive Director, Human Resources Astellas Pharma Inc.
|
Ryoichi Uematsu
|
President, Astellas Analytical Science Laboratories, Inc.
|
Senior Director, Technology Planning & Administration, Technology Astellas Pharma Inc.
|
8. Appointment of Staff Executive Director effective on April 1, 2016
Name | New Title | Current Title |
Mineo Takahashi | Staff Executive Director, Japan Sales & Marketing | Vice President, Distribution Relations, Japan Sales & Marketing |
9. Organizational Changes effective on April 1, 2016
Healthcare Policy & CSR
A corporate division, Healthcare Policy & CSR, will be newly established by consolidating functions responsible for taking actions to improve patient access to health care. Vice President of Healthcare Policy & CSR will report to Chief Strategy Officer.
Medical Information Center
The name of Medical Information Center will be changed to Medical Communications, Japan.
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.
Комментарии